New Experimental Insights for Alleviating the Inflammation of UlcerativeColitis (UC)

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by idiopathic inflammation primarily affecting the mucosa and submucosa of the colon. It manifests with symptoms such as bloody diarrhea, abdominal pain, weight loss, and rectal bleeding, following a relapsing and remitting pattern. UC incidence peaks at ages 15–30 and 50– 70, with an equal gender distribution. This multifactorial disease involves genetic predispositions, environmental influences, epithelial barrier dysfunction, and immunological factors. The intricate interplay between genetic predispositions and environmental triggers continues to shape our understanding of UC, offering potential pathways for targeted therapies and preventive strategies. Despite advances in conventional therapies—including amino-salicylates, corticosteroids, immunomodulators, and biologics—many patients experience treatment failure, loss of response over time, or debilitating side effects such as infections, malignancies, and systemic toxicities. These limitations underscore the urgent need for novel therapeutic approaches that are both more effective and safer. In this review, we highlight recent advances in UC management, focusing on emerging small molecules, novel clinical applications, and therapeutic agents that aim to provide patients with more targeted, durable, and tolerable treatment options.